You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
LUNG CANCER GUIDELINE
Since the approval and launch of Vebreltinib in November 2023, it has successively been recommended in multiple authoritative lung cancer guidelines for the first-line and subsequent-line treatment of NSCLC (Non-Small Cell Lung Cancer) with MET exon 14 skipping alterations at the Grade I level.
-
CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2024 Edition)
[Key Recommendation]: For the first-line and subsequent-line treatment of NSCLC with MET exon 14 skipping alterations in Stage Ⅳ of non-small cell lung cancer: Vebreltinib is newly added as a Grade I recommendation.
-
Chinese Medical Association Guidelines for Clinical Diagnosis and Treatment of Lung Cancer (2024 Edition)
[Key Recommendation]: Treatment of patients with Stage Ⅳ non-small cell lung cancer: Vebreltinib is newly added as a recommendation for the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping alterations.
-
Chinese Guidelines for the Treatment of Stage IV Primary Lung Cancer (2024 Edition)
[Key Recommendation]: Vebreltinib is newly added as a recommended treatment for patients with NSCLC at Stage IV harboring MET exon 14 skipping alterations (Category 2A recommendation).
